On May 12, 2024, the initial results from the Phase 1/2 LAPiS trial using allogeneic induced pluripotent stem cell-derived cardiomyocyte spheroids (HS-001) will be presented at the European Society of Cardiology - Heart Failure 2024 Congress in Lisbon, Portugal. This presentation will cover the data from the initial three patients, including the world first, treated at Tokyo Women's Medical University.

Presentation Details:

The Heart Failure Congress is a globally renowned event where the latest research findings and treatments for heart failure are presented, covering all aspects of the condition. The 2024 congress, held in Lisbon and online, aims to improve the quality of life and longevity through better prevention, diagnosis, and treatment of heart failure under the mission of bringing together the world's leading experts.

Heartseed continues to support the progress of this trial and aims for the early practical application of HS-001.

About Heartseed

Heartseed Inc. was founded in 2015 to develop and commercialize cardiac remuscularization therapy developed by Professor Keiichi Fukuda and his group at the Department of Cardiology, Keio University, Tokyo, Japan. Heartseed has proprietary technologies throughout the entire manufacturing process of the cardiomyocyte-cell product, including purification, cell delivery and iPSC production.

Heartseed announced the global collaboration and license agreement with Novo Nordisk A/S for HS-001 in June 2021. Heartseed received "Minister of Science and Technology Policy Award" at Japan Venture Awards 2021 and "Ministry of Education, Culture, Sports, Science and Technology Award" at Academic Startups 2021, and "Most Promising Pipelines Awards (iPSC)" at Asia Pacific Cell & Gene Therapy Excellence Awards 2022. For more information, visit heartseed.jp, LinkedIn and YouTube.

Contact:
Kikuo Yasui,
COO, Heartseed Inc.
Tel: +81-3-6380-1068
Email: kikuo.yasui@heartseed.jp